Securities Code: 4506

Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2012

February 3, 2012

Dainippon Sumitomo Pharma Co., Ltd.

- Forecasts provided in this document are based on the management's assumptions and beliefs, made in light of information available up to the day of announcement. Actual financial results may differ materially from those presented in this document, being dependent upon a number of factors.
- All values are rounded. Therefore totals may not be consistent with aggregated figures.

I. Consolidated Financial Highlights

1. Consolidated Statements of Income

(Billions of yen)

	FY2010 3Q	FY2011 3Q	Change (%)	FY2010	Change (%)	FY2011 (Forecast)*3	Change (%)
Net sales	280.8	265.2	(5.6)	379.5	28.1	352.0	(7.2)
Cost of sales	83.7	74.0	(11.7)	110.0	(2.0)	99.5	(9.6)
SG&A expenses	170.0	168.9	(0.6)	238.5	60.8	230.5	(3.4)
SG&A expenses less R&D costs	123.7	128.2	3.7	170.4	75.6	173.5	1.8
R&D costs	46.3	40.7	(12.1)	68.2	32.7	57.0	(16.4)
Operating income	27.1	22.3	(17.5)	31.0	(13.1)	22.0	(28.9)
Ordinary income	26.2	22.0	(16.2)	28.6	(15.4)	22.0	(23.1)
Net income	14.8	10.3	(30.5)	16.8	(19.9)	10.0	(40.5)

1: Cost of sales includes provision for (reversal of) reserve for sales returns.
2: Change (%) represent ratio of changes from the corresponding period of the previous year.
3: The forecasts released on October 31, 2011 have been revised.

EBITDA (Billions of yen)	64.0	52.8	78.0	64.0
Earnings per share (yen)	37.22	25.86	42.27	25.17
Return on equity (ROE)	4.4%	3.2%	5.0%	—
Payout ratio	36.3%	52.2%	42.6%	71.5%

2. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2010 3Q	FY2011 3Q
Net cash provided by operating activities	38.9	35.4
Net cash used in investing activities	(2.2)	(2.3)
Net cash used in financing activities	(17.5)	(30.4)
Cash and cash equivalents at the end of period	74.4	83.4

DSP 47.2
U.S. Subsidiary 29.2

3. Financial Results of U.S. Subsidiary（Before Elimination）

(1) Excluding mainly amortization of patent rights and goodwill.

(Billions of yen)

	FY2010 3Q	FY2011 3Q
Net sales	91.8	83.2
Cost of sales	9.0	10.1
SG&A expenses	60.4	65.3
SG&A expenses less R&D costs	44.0	50.9
R&D costs	16.4	14.4
Operating income	22.4	7.9
Ordinary income	22.8	8.1
Extraordinary loss	—	1.2
Net income	14.3	4.4

(2) Mainly amortization of patent rights and goodwill.

(Billions of yen)

	FY2010 3Q	FY2011 3Q
Net sales	—	—
Cost of sales	3.4	—
SG&A expenses	24.0	21.0
Operating income	(27.4)	(21.0)
Ordinary income	(27.4)	(21.0)
Extraordinary loss	2.2	2.4
Net income	(19.7)	(15.7)

4. Currency Exchange Rates

(Billions of yen)

	FY2010 Jan - Sep Average rate	FY2010 Average rate	FY2011 Jan - Sep Average rate	FY2011 (Forecast rate)	Forex sensitivity (2011 Jan-Dec) (Impact of yen strength by 1yen/$)	
Yen / USD	89.5	87.8	80.6	80.0	Net Sales	(1.3)
Yen / RMB	13.2	13.0	12.4	12.0	Operating Income	0.3

5. Capital Expenditures and Depreciation

(Billions of yen)

	FY2010 3Q	FY2011 3Q	Change	FY 2010	FY 2011 (Forecast)	Change
Capital expenditures (including intangible assets)	5.9	5.1	(0.8)	8.7	10.8	2.1
Depreciation and amortization	8.8	8.5	(0.3)	12.3	11.6	(0.7)

Note: Excluding the amortization associated with acquisition of U.S subsidiary

・Major continuing capital expenditure projects for FY2011

Construction operation of new research building in Osaka research center:
Total budget ¥8.7billion, plan to be completed in March 2013

(Reference) Statements of Income (Non-Consolidated)

(Billions of yen)

	FY2010 3Q	FY2011 3Q	Change (%)	FY2011 3Q Group-to-parent ratio
Net sales	170.1	157.5	(7.4)	1.68
Cost of sales	54.0	44.2	(18.2)	
SG&A expenses	83.9	79.0	(5.8)	
SG&A expenses less R&D costs	50.9	49.8	(2.2)	
R&D costs	33.0	29.3	(11.2)	
Operating income	32.2	34.2	6.4	0.65
Ordinary income	31.0	34.2	10.1	0.64
Net income	20.1	21.2	5.3	0.48
Earnings per share (yen)	50.70	53.39		

II. Consolidated Statements of (Comprehensive) Income

1. Consolidated Statements of Income

(Billions of yen)

	FY2010 3Q (A)	FY2011 3Q (B)	(B)-(A)	Change (%)
Net sales	280.8	265.2	(15.6)	(5.6)
Overseas sales	106.6	96.4	(10.2)	(9.6)
〔% of net sales〕	[38.0]	[36.3]		
Cost of sales	83.7	74.0	(9.8)	(11.7)
Gross profit	197.1	191.2	(5.8)	(3.0)
SG&A expenses	170.0	168.9	(1.1)	(0.6)
Labor costs	50.5	52.9	2.4	4.8
Advertising and promotion costs	10.8	12.4	1.5	14.1
Sales promotion costs	9.7	9.7	(0.0)	(0.5)
Depreciation and amortization	26.6	23.7	(2.9)	(11.0)
Other costs	26.0	29.6	3.6	13.7
SG&A expenses less R&D costs	123.7	128.2	4.5	3.7
R&D costs	46.3	40.7	(5.6)	(12.1)
Operating income	27.1	22.3	(4.7)	(17.5)
Non-operating income	2.6	2.0	(0.6)	
Non-operating expenses	3.5	2.4	(1.1)	
Ordinary income	26.2	22.0	(4.2)	(16.2)
Extraordinary income	—	1.2	1.2	
Gain on sales of property, plant and equipment	—	1.2	1.2	
Extraordinary loss	2.2	3.6	1.4	
Impairment loss	2.2	2.4	0.1	
Business structure improvement expenses	—	1.2	1.2	
Income before income taxes and minority interests	24.0	19.6	(4.4)	(18.2)
Income taxes	9.2	9.3	0.1	
Income before minority interests	14.8	10.3	(4.5)	(30.5)
Net income	14.8	10.3	(4.5)	(30.5)

- ・Effect of yen appreciation.
- ・Influence of changing method of summing up sales for Pet Food.
- ・Decreased amortization of patent rights and goodwill.
- ・Increased costs related to LATUDA® launch.
- ・Effect of yen appreciation.
- ・Decrease of industrial property lump-sum.
- ・Decrease of clinical development costs.
- ・Effect of yen appreciation.
- ・Sale of Tokyo Northern Office
- ・Loss from impairment of patent rights
- ・Restructuring changes in U.S subsidiary
- ・Revision of the estimated effective tax rate

Notes 1: Cost of sales includes provision for (reversal of) reserve for sales returns.
2: Overseas sales includes the sales of exports of non-Pharmaceutical products.

2. Consolidated Statements of Comprehensive Income (Loss)

(Billions of yen)

	FY2010 3Q	FY2011 3Q
Income before minority interests	14.8	10.3
Other comprehensive income (loss)	(22.7)	(11.1)
Unrealized gains (losses) on available-for-sale securities, net of tax	(1.9)	0.3
Foreign currency translation adjustment	(20.8)	(11.4)
Comprehensive income (loss)	(7.9)	(0.8)

3. Segment Information（3Q, FY2011）

(Billions of yen)

	Pharmaceuticals Business						Other Business*3	Total
	Japan	North America*1	Amortization *2	China	Other Regions	Subtotal		
Net sales	139.3	79.8	—	4.8	11.3	235.1	30.1	265.2
Sales to customers	139.1	79.8	—	4.8	11.3	234.9	30.3	265.2
Intersegment	0.2	—	—	—	—	0.2	(0.2)	—
Cost of sales	35.5	8.0	—	1.5	5.7	50.7	23.3	74.0
Gross profit	103.8	71.7	—	3.3	5.5	184.4	6.8	191.2
SG&A expenses less R&D costs	49.3	50.9	21.0	2.4	0.2	123.9	4.3	128.2
Income (loss) of segment	54.5	20.8	(21.0)	0.9	5.3	60.5	2.5	63.0
R&D costs						40.2	0.5	40.7
Operating income						20.3	2.0	22.3

Notes *1: Excluding amortization of patent rights and goodwill.

*2: Amortization of patent rights and goodwill.

*3: Includes the elimination of intersegment transaction.

*4: Pharmaceuticals segmentation has been changed since FY2011.
In order to manage R&D costs globally, they are not included in each segment.

(Reference) Segment Information（3Q, FY2010）

(Billions of yen)

	Pharmaceuticals Business						Other Business*3	Total
	Japan	North America*1	Amortization *2	China	Other Regions	Subtotal		
Net sales	140.0	88.5	—	4.2	13.6	246.3	34.5	280.8
Sales to customers	139.9	88.5	—	4.2	13.6	246.2	34.6	280.8
Intersegment	0.1	—	—	—	—	0.1	(0.1)	—
Cost of sales	36.6	9.0	3.4	0.9	6.1	56.0	27.8	83.7
Gross profit	103.4	79.4	(3.4)	3.3	7.5	190.3	6.7	197.1
SG&A expenses less R&D costs	49.0	44.0	24.0	1.9	0.3	119.2	4.5	123.7
Income (loss) of segment	54.4	35.4	(27.4)	1.4	7.3	71.2	2.2	73.4
R&D costs						45.8	0.5	46.3
Operating income						25.4	1.7	27.1

Notes *1: Excluding mainly amortization of patent rights and goodwill.

*2: Mainly amortization of patent rights and goodwill.

*3: Includes the elimination of intersegment transaction.

*4: According to change of segmentation from FY2011, results from FY2010 are recalculated by new segmentation.

Segment Information（FY2011 Forecast） (Billions of yen)

	Pharmaceuticals Business						Other Business	Total
	Japan	North America*1	Amortization *2	China	Other Regions	Subtotal		
Net sales	181.4	108.4	—	6.6	15.3	311.7	40.3	352.0
Sales to customers	181.1	108.4	—	6.6	15.3	311.4	40.6	352.0
Intersegment	0.3	—	—	—	—	0.3	(0.3)	—
Cost of sales	47.5	11.1	—	1.9	7.8	68.3	31.2	99.5
Gross profit	133.9	97.3	—	4.7	7.5	243.4	9.1	252.5
SG&A expenses less R&D costs	66.0	69.9	27.7	3.6	0.3	167.5	6.0	173.5
Income (loss) of segment	67.9	27.4	(27.7)	1.1	7.2	75.9	3.1	79.0
R&D costs						56.2	0.8	57.0
Operating income						19.7	2.3	22.0

Notes *1: Excluding amortization of patent rights and goodwill.

*2: Amortization of patent rights and goodwill.

*3: Pharmaceuticals segmentation has been changed since FY2011.

*4: The forecasts released on Oct 31, 2011 have been revised.

(Reference) Segment Information（FY2010） (Billions of yen)

	Pharmaceuticals Business						Other Business	Total
	Japan	North America*1	Amortization *2	China	Other Regions	Subtotal		
Net sales	183.0	117.6	—	5.7	28.4	334.8	44.7	379.5
Sales to customers	182.9	117.6	—	5.7	28.4	334.6	44.9	379.5
Intersegment	0.2	—	—	—	—	0.2	(0.2)	—
Cost of sales	49.2	12.5	3.3	1.2	8.0	74.2	35.9	110.0
Gross profit	133.9	105.2	(3.3)	4.5	20.4	260.6	8.9	269.5
SG&A expenses less R&D costs	65.7	63.6	31.4	3.3	0.3	164.3	6.1	170.4
Income (loss) of segment	68.2	41.6	(34.7)	1.2	20.1	96.4	2.8	99.1
R&D costs						67.4	0.8	68.2
Operating income						29.0	2.0	31.0

Notes *1: Excluding mainly amortization of patent rights and goodwill.

*2: Mainly amortization of patent rights and goodwill.

*3: According to change of segmentation from FY2011, results from FY2010 are recalculated by new segmentation.

4. Sales of Pharmaceuticals Business (Sales to customers) (Billions of yen)

	FY2010 3Q (A)	FY2011 3Q (B)	(B)-(A)	Change (%)	Progress Rate vs. FY2011 Forecast%	FY2010	FY2011 (Forecast)	
Japan	139.9	139.1	(0.7)	(0.5)	77.2	182.9	[180.2]	181.1
North America	88.5	79.8	(8.7)	(9.9)	73.6	117.6		108.4
China	4.2	4.8	0.5	12.7	72.3	5.7		6.6
Other Regions	13.6	11.3	(2.3)	(17.2)	69.7	28.4	[16.2]	15.3
Overseas Sales Total								
Overseas sales (Pharmaceuticals)	106.3	96.2	(10.2)	(9.6)	73.3	151.7	[131.2]	130.3
% of net sales (Pharmaceuticals)	43.2	40.9				45.3	[42.1%]	41.8

5. Sales of Major Products

Pharmaceuticals (Japan) (Sales figures before reduction of rebates, Billions of yen)

Brand name (Generic name) Therapeutic indication	FY2010 3Q(A)	FY2011 3Q(B)	(B)-(A)	Change (%)	Progress Rate vs. FY2011 Forecast%	FY2010	FY2011 (Forecast)	
AMLODIN® (amlodipine) Therapeutic agent for hypertension and angina pectoris	32.7	28.2	(4.5)	(13.8)	79.5	41.4		35.5
GASMOTIN® (mosapride citrate) Gastroprokinetic	16.0	16.3	0.3	1.7	77.7	21.0		21.0
PRORENAL® (limaprost alfadex) Vasodilator	11.5	12.1	0.6	5.0	78.1	14.9		15.5
MEROPEN® (meropenem) Carbapenem antibiotic	9.9	9.6	(0.3)	(3.1)	86.9	12.6	[11.0]	11.9
AVAPRO® (irbesartan) Therapeutic agent for hypertension	6.1	8.6	2.5	40.6	74.5	8.3		11.5
LONASEN® (blonanserin) Atypical antipsychotic	6.8	7.8	0.9	13.9	70.5	9.0		11.0
REPLAGAL® (agalsidase alfa) Anderson-Fabry disease drug	4.4	7.0	2.5	56.6	78.2	6.2		8.9
EBASTEL® (ebastine) Antiallergic	5.0	4.3	(0.7)	(13.7)	64.3	8.6		6.7
AmBisome® (amphotericin B) Therapeutic agent for systemic fungal infection	3.5	3.5	(0.0)	(1.2)	77.5	4.6		4.5
SUMIFERON® (interferon-αNAMALWA) Natural alpha interferon	4.0	3.0	(1.0)	(24.8)	74.4	5.1		4.0
EXCEGRAN® (zonisamide) Antiepileptic	2.7	2.6	(0.1)	(3.6)	76.4	3.5		3.4
DOPS® (droxidopa) Noradrenergic neural function	2.6	2.5	(0.1)	(1.9)	79.7	3.3		3.2
(Reference)								
MELBIN® (metformin) Biguanide oral hypoglycemic	3.4	0.8	(2.6)	(77.4)	94.6	4.4		0.8
Japan (New products)								
METGLUCO® (metformin) Biguanide oral hypoglycemic (Launch: May 2010)	0.2	5.4	5.2	3,213.7	72.9	0.3		7.4
TRERIEF® (zonisamide) Parkinson's disease drug (Launch: Mar, 2009)	2.7	4.0	1.4	51.1	74.8	3.7		5.4
MIRIPLA® (miriplatin hydrate) Therapeutic agent for hepatocellular carcinoma (Launch: Jan, 2010)	1.2	1.0	(0.2)	(14.5)	72.3	1.5		1.4
SUREPOST® (repaglinide) Rapid-acting insulin secretagogue (Launch: May 2011)	—	0.1	0.1	—	32.2	—		0.2

Notes: Figures in parentheses [ ] are forecasts released on October 31, 2011.

North America (Billions of yen)

Brand name (Generic name) Therapeutic indication	FY2010 3Q (A)	FY2011 3Q (B)	(B)-(A)	Change (%)	Progress Rate vs. FY2011 Forecast%	FY2010	FY2011 (Unaudited)
LUNESTA® (eszopiclone) Sedative hypnotic	41.7	32.6	(9.1)	(21.9)	76.1	53.9	[42.8] 42.1
XOPENEX® (levalbuterol HCl) Short-acting beta-agonist	27.4	24.3	(3.1)	(11.2)	73.8	38.4	[33] 33.4
BROVANA® (arformoterol tartrate) Long-acting beta-agonist	6.9	7.4	0.5	7.4	75.0	9.3	[9.9] 10.2
LATUDA® (lurasidone) Atypical antipsychotic (Launch: Feb, 2011)	—	3.9	3.9	—	53.9	—	[7.2] 6.9
OMNARIS® (ciclesonide) Corticosteroid nasal spray	3.6	3.9	0.3	7.3	73.2	4.8	[5.3] 5.1
ALVESCO® (ciclesonide) Inhaled corticosteroid	1.9	2.0	0.1	6.6	69.4	2.5	[2.9] 2.8
Industrial property revenues	5.3	4.5	(0.8)	(15.1)	84.4	6.6	[5.3] 5.8

China (Billions of yen)

Brand name (Generic name)	FY2010 3Q (A)	FY2011 3Q (B)	(B)-(A)	Change (%)	Progress Rate vs. FY2011 Forecast%	FY2010	FY2011 (Unaudited)
MEROPEN® (meropenem)	3.7	4.0	0.3	9.5	71.7	5.0	[5.6] 5.5

Other Regions (Sales to customers) (Billions of yen)

Brand name (Generic name)	FY2010 3Q (A)	FY2011 3Q (B)	(B)-(A)	Change (%)	Progress Rate vs. FY2011 Forecast%	FY2010	FY2011 (Forecast)
MEROPEN® (meropenem) (Export)	10.5	8.7	(1.7)	(16.7)	68.3	14.5	[12.8] 11.9
EXCEGRAN® (zonisamide) (Export)	1.3	0.9	(0.3)	(24.3)	78.9	1.5	1.2
GASMOTIN® (mosapride citrate) (Export)	0.8	0.7	(0.2)	(20.3)	95.1	1.0	0.7
Industrial property revenues	0.9	0.3	(0.6)	(63.1)	40.5	11.2	0.8

(Reference) Sales of Products of North America Segment (based on local currency) (Millions of dollars)

Brand name (Generic name)	Jan-Sep 2010(A)	Jan-Sep 2011(B)	(B)-(A)	Change (%)	Oct-Dec 2011 (Unaudited)	Jan-Dec 2010 (Actual)	Jan-Dec 2011 (Unaudited)
LUNESTA® (eszopiclone)	466	404	(62)	(13.2)	123	614	[533] 528
XOPENEX® (levalbuterol HCl)	307	302	(4)	(1.4)	117	437	[410] 419
BROVANA® (arformoterol tartrate)	77	92	15	19.3	35	105	[123] 127
LATUDA® (lurasidone)	—	48	48	—	38	—	[90] 86
OMNARIS® (ciclesonide)	40	48	8	19.2	16	54	[66] 64
ALVESCO® (ciclesonide)	21	25	4	18.4	10	29	[35] 35
Industrial property revenues	59	56	(3)	(5.8)	17	76	[65] 72
Others	19	15	(4)	(22.6)	14	25	[26] 28
Total	989	990	1	0.1	369	1,340	[1,348] 1,359

Notes: Figures in parentheses [ ] are forecasts released on October 31, 2011

III. Consolidated Balance Sheets

ASSETS

(Billions of yen)

	As of 2011/03/31 (A)	As of 2011/12/31 (B)	(B)-(A)
[Assets]	589.9	554.2	(35.7)
Current assets:	333.0	324.8	(8.2)
Cash and time deposits	14.9	9.7	(5.2)
Notes and accounts receivable	107.8	102.0	(5.8)
Marketable securities	90.9	93.3	2.4
Inventories	56.0	58.4	2.4
Deferred tax assets	33.5	31.8	(1.7)
Short-term loans	25.0	25.0	—
Others	5.0	4.7	(0.3)
Allowance for doubtful receivables	(0.1)	(0.1)	0.0
Fixed assets:	256.9	229.4	(27.5)
Property, plant and equipment:	69.8	66.8	(3.0)
Buildings and structures	41.7	40.4	(1.3)
Machinery, equipment and carriers	12.1	10.4	(1.7)
Land	10.3	10.2	(0.0)
Construction in progress	0.9	1.4	0.4
Others	4.8	4.4	(0.3)
Intangible assets:	143.3	112.9	(30.4)
Goodwill	70.4	64.3	(6.1)
Patent rights	61.0	37.8	(23.2)
Others	11.9	10.8	(1.1)
Investments and other assets:	43.8	49.7	5.9
Investment securities	27.9	26.9	(1.1)
Deferred tax assets	7.0	13.6	6.6
Others	9.0	9.2	0.2
Allowance for doubtful receivables	(0.1)	(0.1)	0.0
Total assets	589.9	554.2	(35.7)

・The lump-sum amount for the license agreement at the end of the last fiscal year was appropriated for accounts receivable.

・Amortization (18.1)
・Currency translation (2.6)
・Loss from impairment of patent rights (2.4)

Accounts receivable turnover period (in months)	3.41	3.46

LIABILITIES AND NET ASSETS

(Billions of yen)

	As of 2011/03/31 (A)	As of 2011/12/31 (B)	(B)-(A)
[Liabilities]	265.9	238.2	(27.7)
Current liabilities:	157.2	101.9	(55.3)
Notes and accounts payable	15.6	17.7	2.1
Short-term loans payable	50.0	—	(50.0)
Current portion of long-term loans payable	10.6	10.0	(0.6)
Income taxes payable	7.7	8.7	1.0
Reserve for bonuses	7.4	3.9	(3.5)
Reserve for sales returns	2.3	3.1	0.9
Reserve for sales rebates	15.9	17.7	1.8
Accounts payable-other	33.8	25.0	(8.9)
Others	13.8	15.7	1.9
Long-term liabilities:	108.7	136.3	27.6
Bonds payable	50.0	70.0	20.0
Long-term loans payable	43.0	50.5	7.5
Liability for retirement benefits	10.3	10.8	0.5
Others	5.4	5.0	(0.4)
[Net assets]	324.0	316.0	(8.0)
Shareholders' equity:	341.8	344.9	3.1
Common stock	22.4	22.4	—
Capital surplus	15.9	15.9	—
Retained earnings	304.2	307.3	3.1
Treasury stock	(0.6)	(0.6)	(0.0)
Accumulated other comprehensive income (loss):	(17.8)	(28.9)	(11.1)
Unrealized gains on available-for-sale securities, net of tax	5.4	5.7	0.3
Foreign currency translation adjustment	(23.2)	(34.6)	(11.4)
Total liabilities and net assets	589.9	554.2	(35.7)

・Total interest-bearing debt
153.6→130.5（23.1）

・Exchange Rates($)
81.52→76.65

IV. Quarterly Business Results

(Billions of yen)

	FY2010				FY2011		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q
Net sales	101.8	86.8	92.2	98.7	94.8	83.2	87.2
Cost of sales	32.6	25.2	25.9	26.3	25.8	24.0	24.2
SG&A expenses	54.4	61.4	54.2	68.5	56.2	57.3	55.4
SG&A expenses less R&D costs	39.9	43.1	40.7	46.7	42.6	43.7	42.0
R&D costs	14.5	18.3	13.5	21.8	13.6	13.7	13.4
Operating income	14.8	0.1	12.1	3.9	12.8	1.9	7.6
Non-operating income	1.1	0.8	0.7	0.7	1.0	0.5	0.6
Non-operating expenses	1.1	1.4	1.0	2.2	0.6	1.1	0.7
Ordinary income (loss)	14.8	(0.5)	11.8	2.4	13.2	1.3	7.5
Extraordinary income	—	—	—	—	—	1.2	0.0
Extraordinary loss	—	—	2.2	1.3	—	—	3.6
Income (loss) before income taxes and minority interests	14.8	(0.5)	9.6	1.1	13.2	2.6	3.9
Net income (loss)	9.3	(0.6)	6.1	2.0	8.1	1.5	0.7

Note: Cost of sales includes provision for (reversal of) reserve for sales returns.

V. Major consolidated subsidiaries (as of 2011/12/31)

	Domestic			Overseas	
	DSP Gokyo Food & Chemical Co., Ltd.	DS Pharma Animal Health Co., Ltd.	DS Pharma Biomedical Co., Ltd.	Sunovion Pharmaceuticals Inc.	Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
Establishment	October 1947	July 2010	June 1998	January 1984	December 2003
Fiscal year	March 31	March 31	March 31	December 31	December 31
Ownership	100%	100%	100%	100%	100%
Number of employees	145	103	65	2,296	608
Businesses	Manufacturing and sales of food ingredients, food additives, and chemical product materials	Manufacturing, and sales of veterinary medicines, feedstuff, feed additives	Manufacturing and sales of diagnostics and research materials	Manufacturing and sales of pharmaceuticals	Manufacturing and sales of pharmaceuticals

Number of employees (as of 2011/12/31):

7,704 (consolidated)

4,487 (non-consolidated)

Number of MRs (as of 2011/12/31):

Japan	1,410 (excluding managers)	1,620 (including managers)
U.S.	1,260 (excluding managers)	1,390 (including managers)
China	320 (excluding managers)	400 (including managers)

VI. Development Pipeline (as of February 3, 2012)

Major Products under Development in Japan

Stage in JPN	Brand name/ Product code Formulation	Generic name	Proposed Indication	Origin	Remarks
NDA filed	DSP-8153 Oral	amlodipine besilate / irbesartan	Hypertension	In-house	Combination product NDA filed in Nov. 2011
Phase III	AS-3201 Oral	ranirestat	Diabetic neuropathy	In-house	
	SM-13496 Oral	lurasidone hydrochloride	Schizophrenia	In-house	New Phase III study under preparation
	SUREPOST® Oral	repaglinide	(New Indication) Type 2 diabetes Combination therapy with biguanide (New Indication) Type 2 diabetes Combination therapy with thiazolidine	Novo Nordisk	Approved indication: The reduction of postprandial blood glucose in patients with type 2 diabetes Monotherapy Combination with α-GI
	METGLUCO® Oral	metformin hydrochloride	(Addition of pediatric usage) Type 2 diabetes Pediatric usage	Merck Santé	
	LONASEN® Oral	blonanserin	(Addition of pediatric usage) Schizophrenia	In-house	
Phase II	SMP-986 Oral	afacifenacin fumarate	Overactive bladder	In-house	
	PRORENAL® Oral	limaprost alfadex	(New Indication Carpal-tunnel syndrome	In-house (with Ono Pharmaceutical)	Co-development with Ono Pharmaceutical. Approved indication: lumbar spinal canal stenosis, etc.
Phase I/II	WT4869 Injection	TBD	Myelodysplastic syndromes	In-house (with Chugai Pharmaceutical)	Co-development with Chugai Pharmaceutical

Stage in JPN	Brand name/ Product code Formulation	Generic name	Proposed Indication	Origin	Remarks
Phase I	DSP-3025 Collunarium	TBD	Bronchial asthma, Allergic rhinitis	In-house	
	WT4869 Injection	TBD	Solid cancer	In-house (with Chugai Pharmaceutical)	Co-development with Chugai Pharmaceutical
	DSP-6952 Oral	TBD	IBS with constipation, Chronic idiopathic constipation	In-house	
	DSP-1747 Oral	obeticholic acid	Primary biliary cirrhosis (PBC) , Nonalcoholic steatohepatitis (NASH)	Intercept Pharmaceuticals	
	DSP-5990 Injection	ceftaroline fosamil	MRSA Infection	Takeda Pharmaceutical	

[Main revisions since the announcement of October 2011]

DSP-8153	Changed from Phase II to NDA filed (NDA filed in November 2011)
Ranirestat (AS-3201)	Changed from Phase III under preparation to Phase III
LONASEN® (blonanserin) for pediatric usage	Newly added Phase III
DSP-5990	Changed from Phase I under preparation to Phase I

Major Products under Development in Foreign Markets

Stage	Brand name/ Product code Formulation	Generic name	Proposed Indication	Origin	Country/ Area	Remarks
Approved	Ciclesonide Nasal Aerosol Collunarium	ciclesonide	(HFA - New Formulation) Allergic rhinitis	Nycomed	U.S.	Approved in Jan. 2012. Brand name: ZETONNA™
Application submitted	STEDESA™ Oral	eslicarbazepine acetate	Epilepsy-adjunct	BIAL	U.S.	NDA submitted in Mar.2009
	SM-13496 Oral	lurasidone hydrochloride	Schizophrenia	In-house	Canada	NDS submitted in June 2011. Approved countries: U.S
	LATUDA® Oral	lurasidone hydrochloride	(Change of maximum dose) Schizophrenia: 160mg daily	In-house	U.S.	sNDA submitted in June 2011. Approved maximum recommended dose: 80mg daily
Phase III	LATUDA® Oral	lurasidone hydrochloride	(New Indication) bipolar disorder (depression)	In-house	U.S. and Europe, etc.	Approved indication: Schizophrenia :U.S
			(Proposed New Indication) MDD with mixed features		U.S.	
			(New Indication) bipolar disorder (maintenance)		U.S. and Europe, etc.	
	Amrubicin hydrochloride Injection	amrubicin hydrochloride	Small cell lung cancer	In-house	China	Brand name in Japan: CALSED®
	STEDESA™ Oral	eslicarbazepine acetate	Epilepsy-adult monotherapy	BIAL	U.S.	
	Blonanserin Oral	blonanserin	Schizophrenia	In-house	China	Brand name in Japan: LONASEN®
Phase II	SMP-986 Oral	afacifenacin fumarate	Overactive bladder	In-house	U.S. and Europe	

Stage	Brand name/ Product code Formulation	Generic name	Proposed Indication	Origin	Country/ Area	Remarks
Phase I	DSP-8658 Oral	TBD	Type 2 diabetes, Alzheimer's disease	In-house	U.S.	
	SEP-228432 Oral	TBD	Neuropathic pain, Major Depressive Disorder (MDD)	In-house (Sunovion)	U.S.	
	DSP-1053 Oral	TBD	Major Depressive Disorder (MDD)	In-house	U.S.	
	DSP-0565 Oral	TBD	Epilepsy	In-house	U.S.	

[Main revisions since the announcement of October 2011]

Ciclesonide Nasal Aerosol	Changed from "NDA submitted" to "Approved" (U.S.: approved in January 2012)
Blonanserin (brand name in Japan: LONASEN®)	Newly added Phase III (China)
DSP-0565	Newly added Phase I（U.S.）

Major Products under Development by Licensees

Generic / Product code (Brand name in JPN)	Proposed Indication	Status of development
AG-7352	Cancer	Out-licensed to Sunesis Pharmaceuticals Inc. for the worldwide territory in October 2003 Phase III study ongoing in North America by Sunesis (Sunesis' product code: SNS-595)
amrubicin hydrochloride (CALSED®)	Small cell lung cancer	Out-licensed to Celgene (former Pharmion) for the U.S. and European territories in June 2005 Phase III study completed in the U.S. and Europe by Celgene
ranirestat AS-3201	Diabetic neuropathy	Out-licensed to Eisai for the worldwide territory, excluding Japan, in September 2005. Phase II / III study ongoing in the U.S., Canada and Europe by Eisai
droxidopa (DOPS®)	Neurogenic orthostatic hypotension, Intradialytic hypotension, Fibromyalgia	Out-licensed to Chelsea Therapeutics for the worldwide territory, excluding Japan, China, Korea and Taiwan in May 2006. NDA submitted in the U.S. by Chelsea for neurogenic orthostatic hypotension in September 2011. Phase II study of fibromyalgia in the UK are ongoing by Chelsea. Phase II study of intradialytic hypotension completed in the U.S. by Chelsea.
DSP-3025	Bronchial asthma, Allergic rhinitis	Entered into a development and marketing agreement in March 2005. AstraZeneca has the right for the worldwide territory, excluding Japan, China, Korea and Taiwan. Phase II study is ongoing in Europe by AstraZeneca (AstraZeneca's product code: AZD-8848)
eszopiclone	Insomnia	Out-licensed by Sunovion to Eisai for the Japanese territory in July 2007. (Brand name in the U.S.: LUNESTA®) Eisai received approval in Japan in January 2012
lurasidone hydrochloride (SM-13496)	Schizophrenia Bipolar disorder	Entered into a license agreement with Takeda Pharmaceutical for Co-development and exclusive commercialization for the European territory, excluding the United Kingdom in March 2011. Both companies are currently developing lurasidone in Europe (Phase III study stage)

[Main revisions since the announcement of October 2011]

eszopiclone Eisai received approval in Japan (January 2012)

VII. Profile of Major Products under Development (February 3, 2012)

DSP-8153 Hypertension

- Developed in-house
- Combination product of irbesartan (angiotensin II receptor blocker) with evidence for renoprotective effects and amlodipine besilate (calcium channel blocker) with evidence for cerebroprotective and cardioprotective effects. In clinical trials in Japan, DSP-8153 was effective for patients with essential hypertension uncontrolled by irbesartan or amlodipine besilate alone. Moreover, two doses are included in the application for this combination product, irbesartan 100mg/ amlodipine 5mg and irbesartan 100mg/ amlodipine 10mg. If approved, this will be the first combination product in Japan including 10mg of amlodipine.
- Development stage: NDA filed in Japan

LATUDA® (lurasidone hydrochloride) Schizophrenia, Bipolar disorder

- Developed in-house
- LATUDA® (lurasidone hydrochloride) tablets was approved for the treatment of schizophrenia by the U.S. Food and Drug Administration (FDA) in October 2010, and launched by Sunovion in February 2011 in the U.S. LATUDA is an atypical antipsychotic agent which is believed to have an affinity for dopamine D_2, serotonin 5-HT_{2A} and serotonin 5-HT_7 receptors where it has antagonist effects. In addition, LATUDA is a partial agonist at the serotonin 5-HT_{1A} receptor and has no appreciable affinity for histamine or muscarinic receptors. In the clinical trials supporting the U.S. FDA approval, the efficacy of LATUDA for the treatment of schizophrenia was established in four, short-term (6-week), placebo-controlled clinical studies in adult patients who met DSM-IV criteria for schizophrenia. In these studies, LATUDA demonstrated significantly greater improvement versus placebo on the primary efficacy measures [the Positive and Negative Syndrome Scale (PANSS) total score and the Brief Psychiatric Rating Scale-derived from PANSS (BPRSd)] at study endpoint. A total of five short-term placebo controlled clinical trials contributed to the understanding of the tolerability and safety profile of LATUDA.
- Development stage:

  Schizophrenia: NDS submitted in Canada
  sNDA submitted for change of maximum dose in the U.S.
  Phase III under preparation in Japan
  Phase III (Co-development with Takeda Pharmaceutical in Europe)
  In addition, Phase III study is ongoing in the U.S., Europe, etc. to test the hypothesis that LATUDA is effective in the long term maintenance treatment of schizophrenia.

  Bipolar disorder: (depression): Phase III in the U.S. and Europe, etc.
  (maintenance): Phase III in the U.S. and Europe, etc.

  MDD with mixed features: Phase III in the U.S.

STEDESA™ (eslicarbazepine acetate) Epilepsy

- In-licensed from BIAL Portela & C[a], S.A
- STEDESA, the proposed trade name for eslicarbazepine acetate, is a novel voltage-gated sodium channel blocker. STEDESA has been studied in Phase III, multi-center, randomized, placebo-controlled studies, which involved patients from over 20 countries. Patients involved in the studies were required to have at least four partial-onset seizures per month despite treatment with one to three concomitant antiepileptic drugs. After a two-week titration period, patients were assessed over a 12-week maintenance period with

continued follow-up over a one-year, open-label period. The target indication for STEDESA is for adjunctive use in adult patients with partial onset seizures. STEDESA is expected to be safe and tolerable, have clear dose-response correlation and marked and sustained seizure reduction.

- Development stage:

  Epilepsy-adjunct: NDA submitted in March 2009 in the U.S.
  NDA Complete Response received April 2010. Sunovion is committed to seeking FDA approval of STEDESA as a once-daily, adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy in the U.S.

  Epilepsy-adult monotherapy: Phase III in the U.S.

AS-3201 (ranirestat) Diabetic neuropathy

- Developed in-house
- AS-3201 alleviates diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This compound has a stronger inhibitory effect and is longer-acting compared to other drugs in this therapeutic area. Clinical studies have shown AS-3201 to have good penetration into nerve tissues, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose. Based on the results of clinical studies, AS-3201 is expected to show improvement of neuronal function and symptoms related to diabetic neuropathy.
- AS-3201 was out-licensed to Eisai for the overseas territory in September 2005. Eisai is conducting Phase II / III studies in the U.S., Canada and Europe.
- Development stage: Phase III in Japan

SMP-986 Overactive bladder

- Developed in-house
- SMP-986 possesses the dual pharmacological actions of muscarinic receptor antagonism (non-selective) and inhibition of the bladder afferent pathway through Na^+-channel blockade. This compound is being evaluated for its ability to ease urinary urgency and reduce the frequency of both urination and incontinence. The compound has also exhibited the potential to have lower incidence of side effects related to muscarinic receptor antagonism, such as dry mouth.
- Development stage: Phase II in the U.S. and Europe. Phase II in Japan

WT4869 Myelodysplastic syndromes (MDS), Solid cancer

- Co-development with Chugai Pharmaceutical
- WT4869 is being developed as a therapeutic cancer vaccine targeting various types of cancer. It is expected that administration of WT4869 will show efficacy in the treatment of leukemia and other types of cancers that express Wilms' tumor gene 1 (WT1), by inducing WT1-specific cytotoxic T-lymphocytes that have the potential to attack tumor cells.
- Development stage:

  Myelodysplastic syndromes (MDS): Phase I/II in Japan
  Solid cancer: Phase I in Japan

DSP-3025 Bronchial asthma, Allergic rhinitis

- Developed in-house
- An immune response modifier with agonistic activity against Toll-like receptor 7 (TLR7). It is expected to become a therapeutic agent providing long-term disease remission in bronchial asthma and allergic rhinitis.
- A series of promising compounds were identified from drug discovery research for a therapeutic agent

with a novel mechanism of action against allergic disorders. With this as a turning point, we started a research collaboration with AstraZeneca in 2004 and discovered a drug candidate as an outcome based on this research collaboration.

- We entered into a development and marketing agreement with AstraZeneca in March 2005. Under the agreement, we will retain development and commercialization rights in Japan, China, Korea and Taiwan and AstraZeneca will retain development and commercialization rights worldwide excluding the four countries. AstraZeneca is conducting Phase II study in Europe. (AstraZeneca's code name: AZD-8848)
- Development stage: Phase I in Japan

DSP-6952 IBS with constipation, Chronic idiopathic constipation

- Developed in-house
- DSP-6952 is a high affinity serotonin-4 receptor partial agonist with enterokinetic effect. DSP-6952 is expected to be effective for IBS with constipation and chronic idiopathic constipation by increasing complete spontaneous bowel movement.
- Development stage: Phase I in Japan

DSP-1747 Primary biliary cirrhosis (PBC), Nonalcoholic steatohepatitis (NASH)

- In-licensed from Intercept Pharmaceuticals Inc. (Intercept's product code: INT-747)
- DSP-1747 is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist.
- Development stage: Phase I in Japan

DSP-5990 MRSA Infection

- In-licensed from Takeda Pharmaceutical Company Limited (Takeda's product code: TAK-599)
- DSP-5990 is a cephem antibiotic, and has strong activities against gram-positive bacteria including MRSA and multiply-resistant *Streptococcus pneumonia* and also gram-negative bacteria.
- Development stage: Phase I in Japan

DSP-8658 Diabetes, Alzheimer's disease

- Developed in-house
- DSP-8658 is a novel PPARα/γ modulator that exhibits potent antihyperglycemic and lipid lowering activity in several animal models.
- Non-clinical studies suggest that DSP-8658 may offer advantages over marketed PPARγ agonists, particularly with respect to improvements in lipid metabolism and incidence of fluid retention or body weight gain in the treatment of diabetes.
- DSP-8658 may also have the potential as a treatment for Alzheimer's disease as the compound may improve symptomatic cognitive decline and show disease modification with mechanism of reduction in β amyloid by impacting a number of different mechanisms in marketed compounds.
- Development stage: Phase I in the U.S.

SEP-228432 Neuropathic pain, Major Depressive Disorder (MDD)

- Developed in-house (Sunovion)
- SEP-228432 is a new triple unbalanced reuptake inhibitor (TRI) that inhibits reuptake of serotonin, norepinephrine and dopamine. The compound is under development for neuropathic pain and MDD in central nervous system disorders (CNS) area.
- Development stage: Phase I in the U.S.

DSP-1053 Major Depressive Disorder (MDD)

- Developed in-house
- DSP-1053 is a new antidepressant drug candidate that shows an inhibitory effect on serotonin transporter and modulatory effects on monoamine receptors. By these mechanisms, DSP-1053 has exhibited the potential to show early on-set of action and higher efficacy in patients.
- Development stage: Phase I in the U.S.

DSP-0565 Epilepsy

- Developed in-house
- DSP-0565 is a new antiepileptic drug candidate which possesses new mechanisms in addition to blocking actions for sodium and calcium channel. This drug shows potent and broad antiepileptic efficacies in various animal models in which existing drugs do not have effect, it is suggested that DSP-0565 would be a useful therapeutic option for treatment-resistant epilepsy or various types of seizures. Furthermore, since this drug has anti-depressant like action and weaker CNS depressive side effects, it is expected that DSP-0565 would improve quality of life in epileptic patients.
- Development stage: Phase I in the U.S.